CAPLIPOINT2,792.00

Caplin Point Laboratories Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹21,219 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+14.4+12.9
EBITDA Growth+17.3+17.6
EBIT Growth+16.7+18.4
Net Income Growth+17.3+20.1
EPS Growth+17.2+19.5
Total Assets Growth+19.0+26.1
Total Equity Growth+23.0+25.8
Cash from Operations Growth+39.0+21.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.